EGFR and non-small cell lung carcinoma: Two previous retrospective studies showed that single afatinib had PFS of about 12 months as first-line therapy for patients with advanced EGFR-mutated NSCLC, which was similar to the results shown in the LUX-Lung series (PFS of 11–13 months) [6,7,8,30,31].